[Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D002386:Cataract / Q000209:etiology; D002924:Ciliary Body; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D061766:Proton Therapy; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D012307:Risk Factors; D012429:Ruthenium Radioisotopes / Q000627:therapeutic use; D013684:Telangiectasis / Q000209:etiology; D013997:Time Factors; D014604:Uveal Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000532:radiotherapy
D012429:Ruthenium Radioisotopes
Mélanomes uvéaux impliquant le corps ciliaire. Analyse de la survie après protonthérapie ou bêta-curiethérapie par ruthénium-106. A propos de 106 cas.